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VisionNicotine consumption is higher for people within the schizophrenia spectrum compared to controls. This obser-
vation supports the self-medication hypothesis, that nicotine relieves symptoms in, for example, schizophrenia
patients. We tested whether performance in an endophenotype of schizophrenia (visual backward masking,
VBM) is modulated by nicotine consumption in i) smoking and non-smoking schizophrenia patients, their
ﬁrst-degree relatives, and age-matched controls, ii) non-smoking and smoking university students, and iii)
non-smoking, early and late onset nicotine smokers. Overall, our results conﬁrmed that VBM deﬁcits are an
endophenotype of schizophrenia, i.e., deﬁcits were highest in patients, followed by their relatives, students scor-
ing high in Cognitive Disorganisation, and controls. Moreover, we found i) beneﬁcial effects of chronic nicotine
consumption on VBM performance, in particular with increasing age, and ii) little impact of clinical status
alone or in interactionwith nicotine consumption onVBMperformance. Given the younger age of undergraduate
students (up to 30 years) versus controls and patients (up to 66 years), we propose that age-dependent VBMdef-
icits emergewhen schizotypy effects are targeted in populations of a larger age range, but that nicotine consump-
tion might counteract these deﬁcits (supporting the self-medication hypothesis).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is characterized bymultiple deﬁcits including halluci-
nations and higher cognitive functions (e.g. memory, language:
Fatouros-Bergman et al., 2014; Park & Gooding, 2014; Silverstein
et al., 1998). In addition, patients have sensory deﬁcits, such as reduced
P50 suppression and contrast sensitivity (Green et al., 2004; Keefe &
Harvey, 2012; Silverstein & Keane, 2011). Sensory deﬁcits are of partic-
ular interest, because they might cause deﬁcient higher cognitive
functions (Mayer et al., 2012).Moreover, sensory deﬁcits reﬂect vulner-
ability for the disease, i.e., they are endophenotypes of schizophrenia
(Braff et al., 2007; Chkonia et al., 2010; Quednow et al., 2011). Another
evidence for an endophenotype is the fact that sensory deﬁcits are not
restricted to patients but are also evident, though inmilder forms, in rel-
atives of patients (Clementz et al., 2014) and healthy individuals scoring
high on schizotypy (Cadenhead et al., 2014; Koychev et al., 2010; Raine
et al., 1992). Schizotypy is a personality trait with symptoms similar to, BrainMind Institute, School of
Station 19, CH-1015, Lausanne,
9.
. This is an open access article underthe ones of patients with schizophrenia (Claridge, 1997; Kwapil &
Barrantes-Vidal, 2014; Gross, et al., 2014).
Interestingly, controls consume nicotine less frequently and heavily
than patients with schizophrenia (De Leon & Diaz, 2005; Leonard et al.,
2007), their relatives, and individuals scoring high in schizotypy
(Esterberg et al., 2007). This elevated nicotine consumption might be
a formof self-medication, compensating for the dysfunctions associated
with the disease (Evans & Drobes, 2009; Hahn et al., 2013; Kumari &
Postma, 2005; Leonard et al., 2007). First, acute nicotine administration
improved attentional functioning in patients (Kumari et al., 2001). Sec-
ond, smoking nicotine acutely reduced auditory gating deﬁcits in pa-
tients but not controls (Adler et al., 1993; Song et al., 2014). Third,
high scoring schizotypes,whowere chronic smokers, had stronger audi-
tory gating (increased P50 response) compared to non-smokers (Wan
et al., 2007). Fourth, in smooth-pursuit eye movements, chronic
smoking was associated with superior performance in patients but not
in controls (Klein & Andresen, 1991; Myers et al., 2004; Olincy et al.,
1998; Petrovsky et al., 2013b; Smith et al., 2002).
In this line, sensory gating deﬁcits in schizophrenia are associated
with genes related to the nicotinic cholinergic receptors (Bridgman
et al., 2014; De Luca et al., 2004; Freedman et al., 2008; Leonard et al.,
2007; Petrovsky et al., 2013a), particularly, to the receptor alpha 7the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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recent study showed that a single nucleotide polymorphism (SNP) in
the alpha 7 subunit gene correlated with both the diagnosis of schizo-
phrenia and impaired performance in visual backward masking (VBM;
Bakanidze et al., 2013).
In this VBM paradigm, a vernier stimulus (i.e., two vertical lines that
are offset horizontally) is presented on the computer screen. Partici-
pants indicate whether the offset of the lower line is to the right or
left of the upper line. A subsequent grating mask impairs vernier offset
discrimination. This VBM paradigm shows the main characteristics of
an endophenotype of schizophrenia (Chkonia et al., 2010; Herzog
et al., 2013). VBM deﬁcits were much stronger in patients with
schizophrenia than controls (Herzog et al., 2004). First-degree rela-
tives of patients with schizophrenia were impaired with perfor-
mance levels in between the performance levels of controls and
patients. Cappe et al. (2012) found VBM impairments in healthy stu-
dents scoring high as compared to low in Cognitive Disorganisation,
one of the three commonly reported schizotypy dimensions. There
were no correlations of VBM deﬁcits with the positive and negative
schizotypy dimensions.
VBM deﬁcits can be linked to the physiology of the nicotinic system
(Herzog et al., 2013). In themacaquebrain, the nicotinic cholinergic sys-
tem projects to layer IV of the primary visual cortex, the ﬁrst cortical
stage of retinal projections (Disney et al., 2007). The cholinergic modu-
lation enhances target-relevant information (e.g., Deco & Thiele, 2009).
In humans, visual contrast detection performance of grating stimuli was
superior when healthy individuals were exposed to nicotine as com-
pared to a placebo (Smith & Baker-Short, 1993). A weaker cholinergic
system in schizophrenia patients may impede the enhancement of
brieﬂy presented stimuli as they are used in VBM (Herzog et al.,
2013). Hence, nicotine consumption may compensate for sensory im-
pairments, supporting the self-medication hypothesis (Evans & Drobes,
2009; Green, 2006).Table 1
Demographic, clinical and questionnaire data of participants in the three studies.
First study Schizophrenia Patients (N = 120) R
Mean Sd M
Female (n) 26 6
Age 34.97 8.309 3
Age range 18–60 1
Education 12.92 2.55 1
SANS 11.4 5.39
SAPS 10.23 3.56
CPZ 607.63 421.71
VD 60.67 71.01 2
Smokers (n) 87/120 5
Second study: University
Students (N = 80)
Non-Smokers (N = 40)
Mean Sd Mean S
Female (n) 69 CogDis 4.5 2
Age 21.2 2.21 UnEx 3.15 2
Age range 18–30 IntAn 1.8 1
Education University Impnon 2.77 2
VD 10.62 2.9
Smokers (n) 40/80
Third study: University Students
(N = 66)
Non-Smokers (N = 26)
Mean Sd Mean Sd Medi
Female (n) 34 CogDis 4.077 2.99 4
Age 22.3 2.5 UnEx 2.8 2 3
Age range 18–29 IntAn 1.42 1.1 1
Education University FagTot
VD 10.3 1.72
Smokers (n) 40/66 Early:20 Late:20
Abbreviations: Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment
Cognitive Disorganisation (CogDis), Unusual Experiences (UnEx), Introvertive Anhedonia (IntAThe attenuationof the cholinergic activitymaybedirectly causedby the
schizophrenia disease or by the antipsychotic medication (e.g. clozapine,
olanzapine). Schizophrenia patients have an over production of neuro-
transmitters and antipsychotic medication compensates this over produc-
tion by blocking the receptors (Carlsson et al., 1999; Manzella et al., 2015).
In the current study, we had two main goals. First, we investigated
whether VBM deﬁcits are more pronounced in individuals pertaining to
the schizophrenia spectrum compared to controls. Second, for individuals
pertaining to the spectrum, we investigated whether VBM deﬁcits are
more evident in non-smokers than smokers (supporting the self-
medication hypothesis). We tested VBM performance in three studies, in
i) non-smoking and smoking schizophrenia patients, their ﬁrst degree rel-
atives, and age-matched controls, ii) non-smoking and smoking university
students, and iii) another sample of non-smoking and smoking university
studentswith half of themhaving started nicotine consumption before the
age of 16 years (Khuder et al., 1999; Reidpath et al., 2013). Early-onset
drug consumptionmight be indicativeof a strongerproneness for a schizo-
phrenia spectrum disorder (De Leon, 1996; Green, 2006). VBM perfor-
mance of our university students was assessed as a function of their self-
reported schizotypy scores (see also Cappe et al., 2012). According to the
previous literature, we expected VBM deﬁcits to be most pronounced in
patientswith schizophrenia and healthy individuals scoring high in Cogni-
tive Disorganisation. We expected that these VBM deﬁcits would be less
pronounced in smokers, probably even least pronounced in early smokers.
2. Methods
2.1. Participants
All participants had normal or corrected-to-normal vision, with
scores above 0.8 for at least one eye, as determined by the Freiburg Vi-
sual Acuity Test (Bach, 2007). All participants gave written informed
consent after having received comprehensive study information.elatives (N = 113) Controls (N = 91)
ean Sd Mean Sd
1 35
4.38 11.66 34.87 8.85
6–66 19–55
4.19 3.82 15.33 2.68
9.29 20.47 23.08 9.5
4/113 41/91
Smokers (N = 40)
d Median Mean Sd Median
.69 4 CogDis 5.1 2.53 5
.76 3 UnEx 3.45 2.86 3
.77 1 IntAn 1.85 1.52 2
.43 2 Impnon 3.27 1.93 3
Early-Smokers (N = 20) Late-Smokers (N = 20)
an Mean Sd Median Mean Sd Median
CogDis 4.2 2.74 4 CogDis 5.45 2.35 5
UnEx 3.15 2.43 3 UnEx 2.5 1.93 2
IntAn 1.5 1.53 1.5 IntAn 2.4 2.08 2
FagTot 2.75 2.55 2 FagTot 2.25 2.02 2
of Negative Symptoms (SANS), Chlorpromazine (CPZ) equivalent, Vernier Duration (VD),
n), Impulsive Nonconformity (Impnon), FagerströmTotal score (FagTot).
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the Tbilisi Mental Health Hospital or the psychosocial rehabilitation cen-
tre. Control participants were recruited from the general population. We
contacted relatives once patients had agreed to participate. We excluded
participants who reported drug or alcohol abuse or any mental illnesses.
An experienced psychiatrist gave the ﬁnal diagnosis of schizophrenia.
The diagnosis was based on i) an interview based on the SCID (DSM-IV
criteria), ii) the scales for the assessment of negative and positive symp-
toms (SANS and SAPS; Andreasen, 1984a, 1984b), and iii) information
fromclinician–patient interactions. TheGeorgianNational Council on Bio-
ethics in Tiblisi had approved the study.
For the second study, we tested 80 students (69 females, Table 1)
from the University of Lausanne or from the Swiss Federal Institute of
Technology in Lausanne (EPFL). According to self-report, 40 were non-
smokers (32 females). None of these participants reported a history of
neurological or psychiatric illness.
For the third study, we tested 66 university students (34 females,
Table 1). Participants were pre-selected according to whether they were
non-smokers (14 women, 12 men), early smokers (10 women, 10 men)
or late smokers (10 women, 10men). Early and late smokers were divid-
ed according to their age of smoking onset (late smokers started smoking
after 15 years of age; Khuder et al., 1999; Reidpath et al., 2013).Table 2
Means and standard deviations for performances in the VBM task.
First Study
Schizophrenia Relatives
Smo (N = 87) N-Smo (N = 33) Smo (N =
BM 25 (SD+/-) 143.34
(±13.9)
150
(±15.25)
49.98
(±6.53)
BM 5 (SD+/-) 221.83
(±13.99)
236.9
(±19.27)
121.12
(±9.3)
Second Study
CogDis UnEx
High Low High
Smo
(N = 26)
N-Smo
(N = 18)
Smo
(N = 14)
N-Smo
(N = 22)
Smo
(N = 20)
N-Smos
(N = 21)
BM 25
(SD+/-)
28.9
(±2.78)
26.43
(±3.4)
21.47
(±3.03)
25.69
(±2.63)
25.74
(±3.31)
25.45
(±3.27)
BM 5
(SD+/-)
75.98
(±5)
62.07
(±4.8)
53.81
(±6.38)
66.13
(±4.44)
71.14
(±6.19)
59.1
(±3.82)
Third study
Controls Early smo
CogDis CogDis
High (N = 11) Low (N = 15) High (N =
BM 25 (SD+/-) 29.62
(±4.54)
24.18
(±2.76)
30.93
(±5.51)
BM 5 (SD+/-) 55.91
(±5.56)
60.63
(±5.53)
56.53
(±7.31)
UnEx UnEx
High (N = 14) Low (N = 12) High (N =
BM 25 (SD+/-) 29.83
(±3.7)
22.57
(±3.1)
25.54
(±3.8)
BM 5 (SD+/-) 62.43
(±6.2)
54.21
(±4.4)
60
(±4.6)
IntAn IntAn
High (N = 13) Low (N = 13) High (N =
BM 25 (SD+/-) 27.11
(±3.81)
25.86
(±3.38)
28.4
(±4.56)
BM 5 (SD+/-) 58.55
(±6.1)
58.72
(±5.2)
57.04
(±5.82)
Data are given separately for the BM25 and BM5, the smoking groups and “symptom” groups2.2. VBM stimuli and apparatus
The VBM protocol was similar to the ones used before (e.g. Herzog
et al., 2004; Cappe et al., 2012). Participants sat in a dimly illuminated
room at a distance of 5 m from the computer screen.We presented ver-
nier stimuli consisting of two white horizontal bars of 10’ (arc min)
slightly offset in the horizontal direction. The stimuli were presented
on a black background and the offset direction was chosen randomly.
The lower line of the vernier was either offset to the left or right relative
to the upper line. Participants indicated by button presses whether the
offset of the lower line was to the left (left button presses with the left
hand) or right (right button presses with the right hand). Errors were
indicated by an auditory signal. For each subject, we determined the
time that the vernier had to stay on the screen in order to reach 75% cor-
rect responses based on a staircase procedure (see Herzog et al., 2004).
This time is called the vernier duration (VD).We used this individual VD
in the next experimental step, where we presented the vernier with an
offset of 1.15’. A blank screen (inter-stimulus interval (ISI)) and a mask
grating followed the vernier. The grating comprised either 25 verniers
or 5 verniers. Verniers had no offset. Using the adaptive Parametric
Estimation by Sequential Testing (PEST) procedure (Taylor, 1967), we
determined the ISI, for which participants reached 75% correctControls
54) N-Smo (N = 59) Smo (N = 41) N-Smo (N = 50)
74.42
(±7.8)
30.42
(±3.32)
40.25
(±3.8)
159.69
(±10.2)
100.6
(±5.33)
116.68
(±7.35)
IntAn
Low High Low
Smo
(N = 20)
N-Smo
(N = 19)
Smo
(N = 32)
N-Smos
(N = 30)
Smo
(N = 8)
N-Smo
(N = 10)
26.96
(±2.83)
26.66
(±2.57)
25.36
(±2.25)
23.85
(±2.14)
30.28
(±6.04)
32.54
(±4.92)
65.3
(±5.88)
70.05
(±5.14)
67.4
(±4.9)
57.86
(±3.15)
71.48
(±8.68)
83.6
(±5.5)
kers Late Smokers
CogDis
7) Low (N = 13) High (N = 12) Low (N = 8)
25.99
(±3.52)
26.36
(±5.2)
21.92
(±4.4)
63.34
(±4.7)
59.9
(±7.43)
64.22
(±6.35)
UnEx
12) Low (N = 8) High (N = 8) Low (N = 12)
31
(±4.77)
25.18
(±5.7)
24.18
(±4.66)
62.5
(±7.4)
64.52
(±8.25)
59.71
(±6.58)
IntAn
10) Low (N = 10) High (N = 11) Low (N = 9)
27.04
(±4)
23.76
(±4.92)
25.58
(±5.3)
64.87
(±5.32)
62.44
(±8.11)
60.64
(±5.7)
(clinical status in 1st study, schizotypy subscales in 2nd and 3rd study).
Groups
SchizophreniaRelativesControls
SO
A 
(m
s)
250,0
200,0
150,0
100,0
50,0
0,0
Error Bars: +/- 2 SE
BM25
BM5
Fig. 1.Mean SOAs for the different grating conditions as a function of group. Vertical bars
denote 2 SE of the mean. Results showed signiﬁcant main effects of Group and Task (but
no signiﬁcant interaction).
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which is VD plus ISI (see Table 2).
2.3. Self-report questionnaires used in studies 2 and 3
In studies 2 and 3, students ﬁlled in the validated French version
(Sierro et al., in press) of a standardised self-report schizotypy question-
naire (Mason et al., 2005). In study 3, participants additionally ﬁlled-in a
standardised nicotine consumption scale (Heatherton et al., 1991).
2.3.1. Self-report schizotypy questionnaire — short O-Life
The 43-item true–false, short O-LIFE (Mason et al., 2005) measures
schizotypy along 4 dimensions comprising positive schizotypy (Unusu-
al Experiences, UnEx, e.g., “Are your thoughts sometimes so strong that
you can almost hear them?”), negative schizotypy (Introvertive Anhe-
donia, IntAn, e.g., “Do you prefer watching television to going out with
people?”), Cognitive Disorganisation (CogDis, e.g., “Are you easily con-
fused if too much happens at the same time?”) and Impulsive Noncon-
formity (ImpNon, e.g., “Do you at times have an urge to do something
harmful or shocking?). Impnon does not constitute a classical
schizotypy dimension, and measures impulsive, anti-social, and eccen-
tric behaviours. Positive answers (for reverse coded items, negative an-
swers) weight one point. For each dimension, we computed scores by
summing the points, so that higher scores denote higher schizotypy. In-
formation on the French translation including normative values for stu-
dent samples can be found in Sierro et al. (in press).
2.3.2. Self-report questionnaire— Fagerström Test of Nicotine
Dependence (FTND)
The FTND tests for the level of nicotine dependence (Heatherton
et al., 1991). Participants have to judge their smoking behaviour accord-
ing to six questions, such as: “How soon after waking do you smoke
your ﬁrst cigarette?”, “Do you ﬁnd it difﬁcult not to smoke in forbidden
places?”, “Which cigarette would you hate to give up?”, “How many
cigarettes do you smoke per day?”. In the case of questions requiring
yes–no responses, yes responses are scored as 1, and no responses are
scored as 0. For the remaining questions, scores are determined through
responses on a 4-point Likert scale (scores range from 0 to 3). An overall
sum score of 10 indicates highest nicotine dependence and a score of
zero lowest nicotine dependence (Heatherton et al., 1991).
2.4. Data analysis
For study 1, we calculated a 3 × 2 × 2 repeated measures ANOVA
with Group (patients, relatives and controls) and Smoking Habit
(smokers, non-smokers) as between-subject factors and Task (BM25,
BM5) as within-subject factor on mean SOAs.
For studies 2 and 3, we ﬁrst determined separate high and low
schizotypy groups according to a median-split for each O-Life subscale
score (see Table 1, see also Cappe et al., 2012). For study 2, we calculated
3 separate 2 × 2 × 2 repeated measures ANOVAs with Group (high, low
schizotypy group) and Smoking Habit (smokers, non-smokers) as
between-subject factors and Task (BM25, BM5) as within-subject factor
on mean SOAs for UnEx, IntAn and CogDis groups, separately. For study
3, we performed analogue ANOVAs to the ones in study 2, but instead of
two smoking groups, we added three Smoking Groups (non-smokers,
early smokers, late smokers) as between-subject factor. Please note that
for schizotypy, a participant canbepart of thehighgroup in onedimension
and in the low group in another dimension (see also Cappe et al., 2012).
We performed Pearson’s correlations between SOAs in the VBM
(separately for BM25 and BM5 SOAs) and age, symptom scores,
schizotypy scores and FTND scores, respectively.
Kolmogorov–Smirnov tests revealed normal distribution for question-
naire scores and behavioural measures. All p-values were two-tailed, the
α-level was set at 0.05 and all post-hoc tests were Tukey tests.3. Results
3.1. Study 1: testing patients with schizophrenia, relatives and controls
The ANOVA showed a signiﬁcant main effect of Group, F(2, 318) =
54.34, p b 0.001, Smoking Habit, F(1, 318) = 3.95, p = 0.047
(smokers b non-smokers), and Task, F(1,318) = 424,75, p b 0.001
(BM25 b BM5; Table 2). Post-hoc tests showed that schizophrenia pa-
tients had higher SOAs than their relatives (p b 0.001) and controls
(p b 0.001). SOAs were higher in relatives than controls (p = 0.02;
Fig. 1). There were no signiﬁcant 2-way and 3-way interactions (all p
values N 0.2).3.2. Study 2: VBM performance as a function of schizotypy in smokers and
non-smokers
To test whether the O-LIFE subscale scores differed between
smoking groups, we conducted separate ANOVAs on these scale scores
with Smoking Groups as between-subject factor. The ANOVAs were
not signiﬁcant for CogDis scores, F(1,79) = 3.3, p = 0.08, UnEx scores,
F(1,79) = 0.49, p = 0.86, and IntAn scores, F(1,79) = 0.28, p = 0.6.
The ANOVA on CogDis groups showed a signiﬁcant main effect of
Task, F(1, 76) = 298.13, p b 0.001 (BM25 b BM5). We replicated the
main effect of CogDis groups (Cappe et al., 2012) on a one-tailed level,
F(1, 76) = 3.23, p = 0.038 (high N low). The main effect of smoking
groupswas not signiﬁcant, F(1, 76)=0.01, p=0.99. Therewere no sig-
niﬁcant 2-way or 3-way interactions (all p values N 0.2).
The ANOVA on UnEx groups showed again the signiﬁcant main ef-
fect of Task, F(1, 76) = 327.76, p b 0.001 (BM25 b BM5). Neither the
main effect of smoking groups, F(1, 76) = 0.28, p = 0.6, nor the one
on UnEx groups, F(1, 76) = 0.25, p = 0.61, was signiﬁcant. There
were no signiﬁcant 2-way or 3-way interactions (p values N0.45).
The ANOVA on IntAn groups showed again the signiﬁcant main ef-
fect of Task, F(1, 76) = 254.81, p b 0.001 (BM25 b BM5). There was a
signiﬁcant main effect of IntAn groups, F(1,76) = 6.51, p = 0.013
(high b low). The main effect of smoking groups was not signiﬁcant,
F(1,76) = 0.039, p = 0.84. There were no signiﬁcant 2-way and 3-
way interactions (all p values N0.12).
Table 3
Pearson’s correlations between participants’ age, VBM performance (BM25, BM5), symptoms (study 1), O-LIFE scores (studies 2 and 3) and Fagerström scores (study 3).
First Study BM25 BM5 SANS SAPS Second Study BM25 BM5 CogDis UnEx IntAn Third Study BM25 BM5 CogDis UnEx IntAn FagTot
N-smo Controls Age 0.32⁎ 0.41⁎⁎ – – N-smo Age −0.03 0.13 −0.21 −0.58 0.01 N-smo Age 0.08 −0.20 −0.34 −0.26 −0.51⁎⁎
BM25 – 0.72⁎⁎ – – BM25 – 0.47⁎⁎ 0.03 −0.05 −0.29 BM25 – 0.45⁎ 0.22 0.29 0.05
BM5 – – – BM5 – −0.10 −0.27 0.55⁎⁎ BM5 – −0.12 0.21 0.33
SANS – – CogDis – 0.16 0.17 CogDis – 0.64⁎⁎ 0.36
SAPS – – UnExp – 0.26 UnEx – 0.35
IntAn – IntAn –
Relatives Age 0.51⁎⁎ 0.39⁎⁎ – – FagTot
BM25 – 0.72⁎⁎ – –
BM5 – – – Smo Age 0.03 0.20 0.60 −0.62 0.23
SANS – – BM25 – 0.60⁎⁎ 0.27 −0.05 −0.15 Smo Early Age −0.11 0.09 0.40 0.03 0.33 0.51⁎
SAPS – – BM5 – 0.40⁎ 0.11 −0.06 BM25 – 0.62⁎⁎ 0.18 −0.21 0.05 0.00
CogDis – 0.00 −0.11 BM5 – −0.19 −0.07 −0.23 0.14
Schizophrenia Age 0.06 0.06 −0.12 −0.12 UnExp – 0.00 CogDis – 0.17 0.52⁎ 0.20
BM25 – 0.70⁎⁎ −0.14 0.28 IntAn – UnEx – −0.20 0.53⁎
BM5 – −0.08 0.40⁎ IntAn – 0.10
SANS – 0.21 FagTot –
SAPS –
Smo Controls Age 0.35⁎ 0.23 – – Late Age −0.30 −0.21 0.01 0.08 −0.02 0.34
BM25 – 0.52⁎⁎ – – BM25 – 0.77⁎⁎ 0.14 0.03 −0.06 −0.02
BM5 – – – BM5 – −0.10 0.11 0.04 0.00
SANS – – CogDis – 0.04 0.08 −0.31
SAPS – – UnEx – 0.12 0.10
IntAn – −0.24
Relatives Age 0.16 0.21 – – FagTot –
BM25 – 0.78⁎⁎ – –
BM5 – – –
SANS – –
SAPS – –
Schizophrenia Age −0.01 0.02 0.07 0.21
BM25 – 0.73⁎⁎ 0.28⁎⁎ 0.12
BM5 – 0.42⁎⁎ 0.20
SANS – 0.12
SAPS –
Signiﬁcant results are marked by asterisks.
Abbreviations: Smoking (Smo), Non-smoking (N-Smo).
⁎ p ≤ 0.05.
⁎⁎ p ≤ 0.01.
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late and early smokers
To test whether the O-LIFE subscale scores differed between
smoking groups, we conducted separate ANOVAs on these scale scores
with Smoking Groups as between-subject factor. The ANOVAs were
not signiﬁcant for CogDis scores, F(2,63) = 1.63, p = 0.2, UnEx scores,
F(2,63) = 2.48, p = 0.09, and IntAn scores, F(2,63) = 0.47, p = 0.62.
The ANOVA on CogDis groups showed a main effect of Task,
F(1,60) = 289.11, p b 0.0001 (BM25 b BM5). There were no signiﬁcant
main effects of Smoking Groups, F(2, 60) = 0.017, p = 0.94, or CogDis
groups, F(1, 60) = 0.002, p = 0.96. We found an interaction between
Task and CogDis groups, F(1,60) = 6.7, p = 0.012. Yet, post-hoc com-
parisons revealed faster performance in the BM25 than BM5 condition
for both the high CogDis group (p b 0.0001) and low CogDis group
(p b 0.0001). Moreover, the two CogDis groups performed comparably
on both the BM25 condition (p= 0.21) and BM5 condition (p= 0.33).
The ANOVA on UnEx groups showed again the main effect of Task,
F(1,60) = 276.97, p b 0.0001. There were no signiﬁcant main effects
of Smoking Groups, F(2, 60) = 0.86, p = 0.86, and UnEx groups,
F(1,60) = 0.32, p = 0.97, and no signiﬁcant 2-way and 3-way interac-
tions (all p values N 0.53).
The ANOVA on IntAn groups showed again the main effect of Task,
F(1, 60) = 290.04, p b 0.001. There were no signiﬁcant main effects of
Smoking Groups, F(2, 60) = 0.074, p = 0.93, and IntAn groups, F(1,
60) = 0.054, p = 0.82, and no signiﬁcant 2-way interactions and 3-
way interaction (all p values N0.45).
3.4. Correlations in the three studies
Pearson correlation coefﬁcients can be found in Table 3. Across all
studies and groups, higher SOA values in BM25 correlated with higher
SOA values in BM5. For the ﬁrst study, higher age correlatedwith higher
BM25 and BM5 values in most non-smoking groups (controls and rela-
tives, but not patients). The signiﬁcant correlation in the smoking
groupswas found only in controls for BM25. In smoking patients, higher
SANS scores correlated with higher BM25 and BM5 values. In non-
smoking patients, higher SAPS scores correlatedwith higher BM5values.
For the second study, higher IntAn scores correlated with higher
BM5 values in non-smokers. In smokers, higher CogDis scores correlat-
ed with higher BM5 values.
For the third study, higher age correlatedwith higher IntAn scores in
non-smoking participants. Also, higher UnEx scores correlated with
higher CogDis scores. In early smokers, higher age correlated with
higher Fagerström scores and higher UnEx
scores. In addition, higher IntAn scores correlated with higher CogDis
scores. In late smokers, no signiﬁcant correlations were observed.
4. Discussion
Sensory deﬁcits are common within the schizophrenia spectrum
(Cadenhead et al., 2014; Koychev et al., 2010; Silverstein & Keane,
2011) and are often endophenotypes of schizophrenia (Braff et al.,
2007; Chkonia et al., 2010; Quednow et al., 2011). Sensory deﬁcits
may be reduced by nicotine consumption (Kumari et al., 2001; Leonard
et al., 2007). Better sensory functioning was reported for participants
with chronic nicotine consumption (Olincy et al., 1998; Petrovsky
et al., 2013b; Wan et al., 2007) or acute nicotine consumption (Adler
et al., 1993; Kumari et al., 2001). Here, we tested whether VBM perfor-
mance, an endophenotype for schizophrenia (Chkonia et al., 2010), dif-
fers in people within the schizophrenia spectrum depending on their
nicotine consumption.
First, our results support the notion that VBM deﬁcits are an
endophenotype for schizophrenia (Chkonia et al., 2010) because VBM
deﬁcits were highest in patients, followed by their relatives and ﬁnally
controls (see Table 2). Second, we found higher SOAs in the high ascompared to the low CogDis student group in study 2, replicating previ-
ous results (see Cappe et al., 2012). However, we could not replicate the
results in study 3. One reason for the replication failuremay be that effect
size is small and hence, even large sample sizes of participants do not al-
ways lead to signiﬁcant results (Francis, 2012). Third, only in study 1,
smokers had lower SOAs (superior performance) than non-smokers, in-
dependent of illness status. However, we did not ﬁnd this result in stud-
ies 2 and 3. Fourth, age correlated negatively with VBM performance,
mainly in non-smoking controls and relatives in study 1 (age range up
to 66 years, while age range in the student populations was up to
30 years).
Our ﬁndings can be explained in at least three ways. First, nicotine
may not affect VBM performance. This explanation, however, is unlike-
ly. As mentioned before, previous studies found signiﬁcant differences
in other visual tasks such as smooth-pursuit eyemovements or contrast
sensitivity. There is no reason to assume that chronic nicotine effects are
only relevant to these visual functions. Second, effects of nicotine are
often short term and are followed by fast adaptation of nicotinic recep-
tors (Adler et al., 1998; Dome et al., 2010; Girod & Role, 2001). Adler
et al. (1993) found transient effects of nicotine consumption on P50 gat-
ing. However, the beneﬁcial effects of smoking disappeared within
30min after nicotine intake. Thus, only acute nicotine effects might im-
pact VBM performance. A way to test this hypothesis is to administrate
nicotine via a transdermal patch to non-smoking patients and deter-
mine VBM performance. Administration of nicotine with a transdermal
patch improved attention in healthy non-smoking participants (Levin
et al., 1998).
Third, our student samples had a lower nicotine dependence com-
pared to other studies (Brinkmeyer et al., 2011; Rissling et al., 2007).
For example, Brinkmeyer et al. (2011) found a difference on the P50
gating between heavy and light smokers as well as controls. Partici-
pants had much higher Fagerström score than in our study (5.64 vs.
2.75, respectively; we cannot compare study 3 with studies 1 and 2
since the Fagerström test was not applied in studies 1 and 2). There-
fore, performance on the VBM might improve with a higher nicotine
dependence (see also Herzig et al., 2010). Our third study showed
that nicotine dependence increases with age. Also, study one showed
that performance on the VBM task decreases with age (see also
Kunchulia et al., 2014). Hence, the difference of study 1 compared to
studies 2 and 3 may also be explained by the larger number of older
participants in study 1.
In conclusion, there seem to be positive but very small effects of
nicotine consumption on backward masking performance.
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